CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
EP0138854B1
(en)
|
1983-03-08 |
1992-11-04 |
Chiron Mimotopes Pty. Ltd. |
Antigenically active amino acid sequences
|
NZ207394A
(en)
|
1983-03-08 |
1987-03-06 |
Commw Serum Lab Commission |
Detecting or determining sequence of amino acids
|
WO1984003506A1
(en)
|
1983-03-08 |
1984-09-13 |
Commw Serum Lab Commission |
Antigenically active amino acid sequences
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
US6492107B1
(en)
|
1986-11-20 |
2002-12-10 |
Stuart Kauffman |
Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
|
DE229046T1
(de)
|
1985-03-30 |
1987-12-17 |
Marc Genf/Geneve Ballivet |
Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
|
NZ215865A
(en)
|
1985-04-22 |
1988-10-28 |
Commw Serum Lab Commission |
Method of determining the active site of a receptor-binding analogue
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5266684A
(en)
|
1988-05-02 |
1993-11-30 |
The Reagents Of The University Of California |
Peptide mixtures
|
US5571689A
(en)
|
1988-06-16 |
1996-11-05 |
Washington University |
Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
|
US5663143A
(en)
|
1988-09-02 |
1997-09-02 |
Dyax Corp. |
Engineered human-derived kunitz domains that inhibit human neutrophil elastase
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
WO1990005144A1
(en)
|
1988-11-11 |
1990-05-17 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
ATE135373T1
(de)
|
1989-09-08 |
1996-03-15 |
Univ Johns Hopkins |
Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5723286A
(en)
|
1990-06-20 |
1998-03-03 |
Affymax Technologies N.V. |
Peptide library and screening systems
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5770434A
(en)
|
1990-09-28 |
1998-06-23 |
Ixsys Incorporated |
Soluble peptides having constrained, secondary conformation in solution and method of making same
|
US5698426A
(en)
|
1990-09-28 |
1997-12-16 |
Ixsys, Incorporated |
Surface expression libraries of heteromeric receptors
|
DE69130831T2
(de)
|
1990-11-21 |
1999-09-16 |
Iterex Pharmaceuticals Ltd. Partnership, San Diego |
Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
AU675916B2
(en)
|
1991-06-14 |
1997-02-27 |
Genentech Inc. |
Method for making humanized antibodies
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
US5270170A
(en)
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
DE69333807T2
(de)
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
Marker für krebs und biosynthetisches bindeprotein dafür
|
NZ258392A
(en)
|
1992-11-13 |
1997-09-22 |
Idec Pharma Corp |
Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
GB9314893D0
(en)
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
US5529925A
(en)
|
1993-12-03 |
1996-06-25 |
St. Jude Children's Research Hospital |
Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
|
EP0659439B1
(en)
|
1993-12-24 |
2001-10-24 |
MERCK PATENT GmbH |
Immunoconjugates
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
US5654307A
(en)
|
1994-01-25 |
1997-08-05 |
Warner-Lambert Company |
Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
WO1996040210A1
(en)
|
1995-06-07 |
1996-12-19 |
Imclone Systems Incorporated |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
PT836605E
(pt)
|
1995-07-06 |
2002-07-31 |
Novartis Ag |
Pirrolopirimidinas e processos para a sua preparacao
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
PL190489B1
(pl)
|
1996-04-12 |
2005-12-30 |
Warner Lambert Co |
Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
|
PT912559E
(pt)
|
1996-07-13 |
2003-03-31 |
Glaxo Group Ltd |
Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
WO1998050038A1
(en)
|
1997-05-06 |
1998-11-12 |
American Cyanamid Company |
Use of quinazoline compounds for the treatment of polycystic kidney disease
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
CA2293829C
(en)
|
1997-06-24 |
2011-06-14 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
EP1028751B1
(en)
|
1997-10-31 |
2008-12-31 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
JP2001522802A
(ja)
|
1997-11-06 |
2001-11-20 |
アメリカン・サイアナミド・カンパニー |
大腸ポリープを治療するためのチロシンキナーゼインヒビターとしてのキナゾリン誘導体の使用
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
EP1034298B1
(en)
|
1997-12-05 |
2011-11-02 |
The Scripps Research Institute |
Humanization of murine antibody
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
JP2002510481A
(ja)
|
1998-04-02 |
2002-04-09 |
ジェネンテック・インコーポレーテッド |
抗体変異体及びその断片
|
ES2340112T3
(es)
|
1998-04-20 |
2010-05-28 |
Glycart Biotechnology Ag |
Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
|
US6335155B1
(en)
|
1998-06-26 |
2002-01-01 |
Sunesis Pharmaceuticals, Inc. |
Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
|
EE200100271A
(et)
|
1998-11-19 |
2002-10-15 |
Warner-Lambert Company |
N-[4-(3-kloro-4-fluorofenüülamino)-7-(3-morfoliin-4-üülpropoksü)kinasoliin-6-üül]ak rüülamiid kui türosiinkinaaside pöördumatu inhibiitor
|
WO2000039585A1
(en)
|
1998-12-28 |
2000-07-06 |
Sunesis Pharmaceuticals, Inc. |
Identifying small organic molecule ligands for binding
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Hakko Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
UA72946C2
(uk)
|
1999-11-05 |
2005-05-16 |
Астразенека Аб |
Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
|
IL149809A0
(en)
|
1999-12-15 |
2002-11-10 |
Genentech Inc |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
PT1242438E
(pt)
|
1999-12-29 |
2007-02-28 |
Immunogen Inc |
Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico
|
KR20020093029A
(ko)
|
2000-04-11 |
2002-12-12 |
제넨테크, 인크. |
다가 항체 및 그의 용도
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
EP1331266B1
(en)
|
2000-10-06 |
2017-01-04 |
Kyowa Hakko Kirin Co., Ltd. |
Cells producing antibody compositions
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
JP3523245B1
(ja)
|
2000-11-30 |
2004-04-26 |
メダレックス,インコーポレーテッド |
ヒト抗体作製用トランスジェニック染色体導入齧歯動物
|
NZ592087A
(en)
|
2001-08-03 |
2012-11-30 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
MXPA04003798A
(es)
|
2001-10-25 |
2004-07-30 |
Genentech Inc |
Composiciones de glicoproteina.
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
JPWO2003084569A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物含有医薬
|
US20040259150A1
(en)
|
2002-04-09 |
2004-12-23 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
|
AU2003236015A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition
|
CN102911987B
(zh)
|
2002-04-09 |
2015-09-30 |
协和发酵麒麟株式会社 |
基因组被修饰的细胞
|
JP4832719B2
(ja)
|
2002-04-09 |
2011-12-07 |
協和発酵キリン株式会社 |
FcγRIIIa多型患者に適応する抗体組成物含有医薬
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
JP4753578B2
(ja)
|
2002-06-03 |
2011-08-24 |
ジェネンテック, インコーポレイテッド |
合成抗体ファージライブラリー
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
BRPI0316779B1
(pt)
|
2002-12-16 |
2020-04-28 |
Genentech Inc |
anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
|
US20050079574A1
(en)
|
2003-01-16 |
2005-04-14 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
DK1454992T3
(da)
|
2003-03-07 |
2006-10-02 |
Ist Naz Stud Cura Dei Tumori |
Anaplastisk lymfomakinaseassay, reagenser og sammensætninger deraf
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
AU2004259012C1
(en)
|
2003-07-23 |
2012-08-02 |
Exelixis, Inc. |
Anaplastic lymphoma kinase modulators and methods of use
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
JP4607879B2
(ja)
|
2003-08-15 |
2011-01-05 |
ノバルティス アーゲー |
新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン
|
GB0321710D0
(en)
|
2003-09-16 |
2003-10-15 |
Novartis Ag |
Organic compounds
|
US20080241884A1
(en)
|
2003-10-08 |
2008-10-02 |
Kenya Shitara |
Fused Protein Composition
|
CA2542125A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
|
SI2380911T1
(en)
|
2003-11-05 |
2018-07-31 |
Roche Glycart Ag |
ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION
|
DK2489364T3
(en)
|
2003-11-06 |
2015-03-02 |
Seattle Genetics Inc |
Monomethylvaline compounds conjugated to antibodies
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
RU2386638C2
(ru)
|
2004-03-31 |
2010-04-20 |
Дженентек, Инк. |
Гуманизированные анти-тфр-бета-антитела
|
US7973061B2
(en)
|
2004-03-31 |
2011-07-05 |
Exelixis, Inc. |
Anaplastic lymphoma kinase modulators and methods of use
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
RU2368622C2
(ru)
|
2004-04-13 |
2009-09-27 |
Ф.Хоффманн-Ля Рош Аг |
Антитела к р-селектину
|
DE602005020799D1
(de)
|
2004-08-05 |
2010-06-02 |
Genentech Inc |
Humanisierte anti-cmet-antagonisten
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
AU2005286607B2
(en)
|
2004-09-23 |
2011-01-27 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
TW200639163A
(en)
|
2005-02-04 |
2006-11-16 |
Genentech Inc |
RAF inhibitor compounds and methods
|
WO2007002433A1
(en)
|
2005-06-22 |
2007-01-04 |
Plexxikon, Inc. |
Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
|
NZ567140A
(en)
|
2005-10-07 |
2011-09-30 |
Exelixis Inc |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
EP1957531B1
(en)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
WO2007064919A2
(en)
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
NZ568654A
(en)
|
2005-12-05 |
2012-02-24 |
Pfizer Prod Inc |
Method of treating abnormal cell growth
|
RU2008142833A
(ru)
|
2006-03-30 |
2010-05-10 |
Новартис АГ (CH) |
КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ К c-Met
|
US7601716B2
(en)
|
2006-05-01 |
2009-10-13 |
Cephalon, Inc. |
Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
|
AR060871A1
(es)
|
2006-05-09 |
2008-07-16 |
Genentech Inc |
Union de polipeptidos con supercontigos optimizados
|
DE602007011923D1
(de)
|
2006-06-02 |
2011-02-24 |
Aveo Pharmaceuticals Inc |
Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine
|
KR100829972B1
(ko)
|
2006-07-14 |
2008-05-16 |
재단법인서울대학교산학협력재단 |
항-hgf/sf 인간화 항체 및 이의 제조방법
|
US8106004B2
(en)
|
2006-07-28 |
2012-01-31 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
CA2598893C
(en)
|
2006-10-11 |
2012-04-10 |
Astellas Pharma Inc. |
Eml4-alk fusion gene
|
EP2222647B1
(en)
|
2006-10-23 |
2015-08-05 |
Cephalon, Inc. |
Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
|
EA019966B1
(ru)
|
2006-12-08 |
2014-07-30 |
АйАрЭм ЭлЭлСи |
Соединения и композиции в качестве ингибиторов протеинкиназы
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
US20090175869A1
(en)
*
|
2007-05-31 |
2009-07-09 |
Ascenta Therapeutics, Inc. |
Pulsatile Dosing of Gossypol for Treatment of Disease
|
TWI389893B
(zh)
|
2007-07-06 |
2013-03-21 |
Astellas Pharma Inc |
二(芳胺基)芳基化合物
|
EP2014681A1
(en)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
EP2042191B1
(en)
|
2007-09-28 |
2013-01-02 |
Roberto Chiarle |
Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination
|
EP2235064B1
(en)
|
2008-01-07 |
2015-11-25 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
BRPI0908268A2
(pt)
|
2008-02-29 |
2018-10-30 |
Array Biopharma Inc |
compostos do inibidor de raf e seus métodos de uso
|
JP2011513329A
(ja)
|
2008-02-29 |
2011-04-28 |
アレイ バイオファーマ、インコーポレイテッド |
RAF阻害化合物として使用されるイミダゾ[4,5−b]ピリジン誘導体
|
JP2011513330A
(ja)
|
2008-02-29 |
2011-04-28 |
アレイ バイオファーマ、インコーポレイテッド |
Raf阻害化合物およびその使用方法
|
EP2265574A1
(en)
|
2008-02-29 |
2010-12-29 |
Array Biopharma, Inc. |
N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
|
WO2009132202A2
(en)
|
2008-04-24 |
2009-10-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
US8124389B2
(en)
|
2008-05-07 |
2012-02-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Crystal structure of aldehyde dehydrogenase and methods of use thereof
|
PA8849001A1
(es)
|
2008-11-21 |
2010-06-28 |
Lilly Co Eli |
Anticuerpos de c-met
|
US20100135983A1
(en)
*
|
2008-12-02 |
2010-06-03 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Anti-inflammatory compositions and methods
|
EP2287197A1
(en)
|
2009-08-21 |
2011-02-23 |
Pierre Fabre Medicament |
Anti-cMET antibody and its use for the detection and the diagnosis of cancer
|
KR101671378B1
(ko)
|
2009-10-30 |
2016-11-01 |
삼성전자 주식회사 |
c-Met에 특이적으로 결합하는 항체 및 그의 용도
|
KR101748707B1
(ko)
|
2009-11-27 |
2017-06-20 |
삼성전자주식회사 |
c-Met에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
|